Physician profile
Warren T Pickard
NPI 1265659288
$4,093.63
in general payments reported to CMS, 2019-2025
37 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $192 · 2022: $474 · 2023: $747 · 2024: $858 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,628.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $426.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $419.21 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $357.40 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $341.77 | 2019-2025 | Airsupra, Lokelma |
| Pfizer INC. | $338.44 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.93 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $191.53 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $185.16 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $142.88 | 2019-2025 | Veozah |
| Ironwood Pharmaceuticals, INC | $138.80 | 2019-2024 | Linzess |
| Otsuka America Pharmaceutical, INC. | $124.94 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $123.52 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $113.17 | 2022-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $106.87 | 2019-2024 | |
| Amgen INC. | $105.44 | 2019-2025 | Evenity, Prolia, Otezla |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $82.64 | 2019-2024 | Verquvo, Belsomra, Gardasil 9 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.81 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $60.35 | 2023-2025 | |
| Lundbeck LLC | $54.98 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $53.43 | 2019-2023 | Xarelto |
| Irhythm Technologies, INC. | $50.47 | 2024 | Zio Monitor, Zio Xt Patch |
| Biohaven Pharmaceutical Holding Company LTD. | $48.99 | 2022 | |
| Dexcom, INC. | $46.33 | 2023-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $42.15 | 2019 | |
| Amarin Pharma, INC. | $40.11 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $39.39 | 2022-2023 | Gvoke Hypopen |
| Corcept Therapeutics | $24.41 | 2025 | Korlym |
| Aimmune Therapeutics, INC. | $24.02 | 2024 | |
| Vanda Pharmaceuticals INC. | $19.57 | 2025 | Hetlioz, Fanapt |
| Corium, LLC | $18.92 | 2023 | Adlarity |
| Tolmar, INC. | $18.56 | 2025 | Jatenzo |
| Medtronic, INC. | $17.31 | 2024 | Intellis Adaptivestim |
| Actelion Pharmaceuticals US, INC. | $14.17 | 2024 | Uptravi, Opsumit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.10 | 2025 | Xifaxan |
| Inspire Medical Systems, INC. | $13.67 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $13.66 | 2022 | |
| Allergan, INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Pickard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.